论文部分内容阅读
目的探讨帕米磷酸二钠注射液治疗恶性肿瘤骨转移所致高钙血症的临床疗效及安全性。方法选择52例诊断为恶性肿瘤骨转移所致高钙血症的患者为研究对象,随机分为研究组和对照组,每组各26例。研究组患者采用帕米磷酸二钠治疗,对照组患者采用唑来磷酸治疗。两组均每月治疗1次,共治疗6个月。比较两组患者的血钙(Ca)、血磷(P)、甲状腺旁素(PTH)、碱性磷酸酶(AKP)、骨钙素(BGP)以及骨密度(BMD)的差异,随访6个月比较两组的临床疗效、止痛效果、转移灶改善、KPS评分及不良反应发生率的差异。结果与对照组相比,研究组患者的Ca、PTH、AKP、BGP和BMD均显著降低,而研究组的血P则显著升高(P<0.05);研究组的总有效率较高,各种不良反应发生率较高(P<0.05),而止痛效果、转移灶改善、KPS评分与对照组相比差异无统计学意义(P>0.05)。结论帕米磷酸二钠治疗恶性肿瘤骨转移所致高钙血症的临床疗效显著,但不良反应较多。
Objective To investigate the clinical efficacy and safety of pamidronate disodium injection in the treatment of hypercalcemia due to bone metastasis of malignant tumors. Methods Fifty-two patients diagnosed as hypercalcemia due to bone metastasis of malignant tumor were selected as study subjects and randomly divided into study group and control group, with 26 cases in each group. Study group patients treated with pamidronate disodium, the control group of patients treated with zoledronic acid. Two groups were treated once a month for a total of 6 months. The differences of serum Ca, P, PTH, BGP, BGP and BMD between the two groups were compared and followed up for 6 months The clinical efficacy, analgesic effect, improvement of metastasis, KPS score and incidence of adverse reactions were compared between the two groups. Results Compared with the control group, Ca, PTH, AKP, BGP and BMD in the study group were significantly decreased, while the study group’s blood P was significantly increased (P <0.05); the study group, the total effective rate, The incidence of adverse reactions was higher (P <0.05), while analgesic effect, metastasis improvement, KPS score was not significantly different from the control group (P> 0.05). Conclusion The efficacy of disodium pamidronate in the treatment of hypercalcemia due to bone metastases of malignant tumors is significant, but there are more adverse reactions.